Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by abrdn plc

abrdn plc lowered its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 8.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,650 shares of the company's stock after selling 8,905 shares during the quarter. abrdn plc owned 0.24% of Tarsus Pharmaceuticals worth $5,185,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $53,000. FMR LLC increased its holdings in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after buying an additional 3,537 shares during the last quarter. SG Americas Securities LLC increased its holdings in Tarsus Pharmaceuticals by 87.5% in the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after buying an additional 3,379 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Tarsus Pharmaceuticals by 64.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company's stock valued at $241,000 after buying an additional 2,879 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at about $249,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TARS shares. Guggenheim reissued a "buy" rating on shares of Tarsus Pharmaceuticals in a report on Monday. Barclays boosted their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a report on Monday, January 27th. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Finally, The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $56.00.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS traded down $0.10 during trading on Thursday, hitting $52.23. 439,489 shares of the company traded hands, compared to its average volume of 639,234. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -13.71 and a beta of 1.01. The business's fifty day moving average is $52.10 and its 200-day moving average is $41.37. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.